A randomized, double-blind, placebo-controlled multicenter clinical study of Xifeng Huashi Granules in the treatment of diarrheal irritable bowel syndrome
- Conditions
- Diarrhea Predominant Irritable Bowel Syndrome
- Registration Number
- ITMCTR2000004143
- Lead Sponsor
- Jiangsu Provincial Hospital of Integrated Traditional Chinese and Western Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- Not specified
1. In line with the diagnostic criteria of WESTERN medicine IBS-D;
2. In line with the standard of TCM syndrome diagnosis of liver depression and spleen deficiency;
3. Aged 18-70 (including 18 and 70 years old) years;
4. Informed consent, voluntary test. The process of obtaining informed consent should comply with ethical principles.
1. Patients with organic gastrointestinal diseases;
2. Patients with severe heart, liver, kidney, respiratory, blood and endocrine diseases;
3. Patients with mental illness and severe neurosis;
4. Women who are pregnant, breastfeeding or planning to have a pregnancy;
5. Those who had taken antibiotics or probiotics or gastrointestinal motility drugs within 1 month before the included test;
6. Poor compliance with medical advice, patients allergic to this drug;
7. Patients who are participating in other clinical studies.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clinical overall efficacy evaluation;
- Secondary Outcome Measures
Name Time Method psychological state;TCM syndromes;The recurrence rate;IBS-quality of life;IBS symptom severity;